Bone Mineral Disorder in Chronic Kidney Disease: Klotho and FGF23; Cardiovascular Implications
Overview
Authors
Affiliations
Cardiovascular factors are one of the main causes of morbidity and mortality in patients with chronic kidney disease. Bone mineral metabolism disorders and inflammation are pathological conditions that involve increased cardiovascular risk in chronic kidney disease. The cardiovascular risk involvement of bone mineral metabolism classical biochemical parameters such as phosphorus, calcium, vitamin D and PTH is well known. The newest markers, FGF23 and klotho, could also be implicated in cardiovascular disease.
Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health.
Bellone F, Cinquegrani M, Nicotera R, Carullo N, Casarella A, Presta P Int J Mol Sci. 2022; 23(9).
PMID: 35563672 PMC: 9099759. DOI: 10.3390/ijms23095282.
Investigation on urinary and serum alpha klotho in dogs with chronic kidney disease.
Yi H, Lee J, Lee K, Oh Y, Song K, Seo K BMC Vet Res. 2020; 16(1):246.
PMID: 32677951 PMC: 7364505. DOI: 10.1186/s12917-020-02458-5.
Mechanism of Action and Clinical Attributes of Auryxia (Ferric Citrate).
Ganz T, Bino A, Salusky I Drugs. 2019; 79(9):957-968.
PMID: 31134521 PMC: 6562046. DOI: 10.1007/s40265-019-01125-w.
Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.
Latko M, Czyrek A, Porebska N, Kucinska M, Otlewski J, Zakrzewska M Cells. 2019; 8(5).
PMID: 31091809 PMC: 6562592. DOI: 10.3390/cells8050455.
The role of klotho in chronic kidney disease.
Zou D, Wu W, He Y, Ma S, Gao J BMC Nephrol. 2018; 19(1):285.
PMID: 30348110 PMC: 6198535. DOI: 10.1186/s12882-018-1094-z.